ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 973,03
-0,43%
Dow Jones
44 303,40
-0,99%
DAX
21 787,00
-0,58%
Brent Oil
74,565
0,00%
Bitcoin
96 637,04
0,18%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Anavex Life Sciences Corporation (AVXL)

  7. Anavex Life Sciences Corporation (AVXL) Actualités

AVXL

Anavex Life Sciences (AVXL)

Anavex Life Sciences Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVXL
DateHeureSourceTitreSymboleSociété
05/02/202513h30GlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025NASDAQ:AVXLAnavex Life Sciences Corporation
27/01/202513h30GlobeNewswire Inc.Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property PortfolioNASDAQ:AVXLAnavex Life Sciences Corporation
18/01/202503h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
15/01/202513h30GlobeNewswire Inc.Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s DiseaseNASDAQ:AVXLAnavex Life Sciences Corporation
13/01/202513h30GlobeNewswire Inc.New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease PatientsNASDAQ:AVXLAnavex Life Sciences Corporation
06/01/202513h30GlobeNewswire Inc.Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
23/12/202422h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AVXLAnavex Life Sciences Corporation
23/12/202413h30GlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business UpdateNASDAQ:AVXLAnavex Life Sciences Corporation
23/12/202413h00GlobeNewswire Inc.Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s DiseaseNASDAQ:AVXLAnavex Life Sciences Corporation
16/12/202413h30GlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024NASDAQ:AVXLAnavex Life Sciences Corporation
09/12/202413h30GlobeNewswire Inc.Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
02/12/202413h30GlobeNewswire Inc.Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024NASDAQ:AVXLAnavex Life Sciences Corporation
26/11/202413h30GlobeNewswire Inc.Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMANASDAQ:AVXLAnavex Life Sciences Corporation
25/11/202413h30GlobeNewswire Inc.Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease JournalNASDAQ:AVXLAnavex Life Sciences Corporation
31/10/202409h00GlobeNewswire Inc.Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024NASDAQ:AVXLAnavex Life Sciences Corporation
23/10/202414h03InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) Software Company AcquisitionNASDAQ:AVXLAnavex Life Sciences Corporation
17/10/202413h30GlobeNewswire Inc.Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaNASDAQ:AVXLAnavex Life Sciences Corporation
15/10/202414h21InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory ManagementNASDAQ:AVXLAnavex Life Sciences Corporation
01/10/202413h00InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading TodayNASDAQ:AVXLAnavex Life Sciences Corporation
03/09/202413h30GlobeNewswire Inc.Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024NASDAQ:AVXLAnavex Life Sciences Corporation
06/08/202423h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVXLAnavex Life Sciences Corporation
06/08/202413h30GlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateNASDAQ:AVXLAnavex Life Sciences Corporation
01/08/202413h30GlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024NASDAQ:AVXLAnavex Life Sciences Corporation
30/07/202423h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVXLAnavex Life Sciences Corporation
30/07/202413h30GlobeNewswire Inc.Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
29/07/202423h21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AVXLAnavex Life Sciences Corporation
28/07/202423h00GlobeNewswire Inc.Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
20/06/202413h30GlobeNewswire Inc.Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
22/05/202413h30GlobeNewswire Inc.Anavex Life Sciences Announces Expansion of Leadership TeamNASDAQ:AVXLAnavex Life Sciences Corporation
14/05/202413h30GlobeNewswire Inc.Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQNASDAQ:AVXLAnavex Life Sciences Corporation
 Showing the most relevant articles for your search:NASDAQ:AVXL

Dernières Valeurs Consultées

NASDAQI
SX5010PI
OMX Stockholm Constructi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces